CSL to Invest $1.5 Billion in Expansion of Illinois Plasma Therapy Facility
Introduction
CSL has announced a $1.5 billion expansion of its manufacturing facility. The expansion will significantly increase production of plasma-derived therapies and albumin, supporting patients with rare and serious conditions while boosting the local economy.
Features
The expanded facility will incorporate CSL’s Horizon 2 manufacturing process, a patented technology designed to improve the yield of immunoglobulin from plasma.
This next-generation approach enhances production efficiency and supports the growing global demand for plasma-derived therapies.
The Kankakee site will also gain advanced manufacturing capabilities, helping the company produce life-saving treatments for conditions such as primary immunodeficiency, hemophilia, hereditary angioedema, trauma, burns, shock, and certain maternal health emergencies.
The expansion will create at least 300 new pharmaceutical jobs and around 800 construction and related roles, bringing the facility’s workforce to more than 1,500 full-time employees.
Construction is underway, with the expanded facility expected to be operational by 2031.
Specifications
| Name | CSL |
| Budget | $1.5 Billion |
| Type | Expansion |
| Year of Completion | 2031 |
